Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 25, 2023
Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function
Monica F Chen, Guilherme Harada, Dazhi Liu, et al.
The American Journal of Surgical Pathology
|
October 17, 2025
Clinicopathogenomic Characteristics of Primary and Metastatic Melanomas With RAF1 and BRAF Fusions
Cecilia Lezcano, Israel S Kasago, Haiming Tang, et al.
JAMA Oncology
|
January 30, 2025
Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy
Sarah E Lochrin, Hannah L Kalvin, James W Smithy, et al.
Translational Vision Science & Technology
|
April 25, 2015
Confocal Adaptive Optics Imaging of Peripapillary Nerve Fiber Bundles: Implications for Glaucomatous Damage Seen on Circumpapillary OCT Scans
Donald C Hood, Monica F Chen, Dongwon Lee, et al.
JCO Precision Oncology
|
June 1, 2023
Response to Repotrectinib After Development of <i>NTRK</i> Resistance Mutations on First- and Second-Generation TRK Inhibitors
Monica F Chen, Soo-Ryum Yang, Jinru Shia, et al.
JCO Precision Oncology
|
May 15, 2025
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With <i>EGFR</i>-Mutant Lung Cancer Treated With Osimertinib
Monica F Chen, Mark Y Jeng, Jennifer Ma, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 30, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination
James W Smithy, Victoria Ciallella, Claire Thant, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 29, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination
James W Smithy, Victoria Ciallella, Claire Thant, et al.
JTO Clinical and Research Reports
|
August 30, 2023
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced <i>ALK</i>- or <i>ROS1</i>-Rearranged NSCLC: A Brief Report
Rohit Thummalapalli, Noura J Choudhury, Fiona Ehrich, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
August 23, 2023
Superior sulcus non-small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management
Kaitlin McLaughlin, Kay See Tan, Joe Dycoco, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 25, 2023
Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function
Monica F Chen, Guilherme Harada, Dazhi Liu, et al.
The American Journal of Surgical Pathology
|
October 17, 2025
Clinicopathogenomic Characteristics of Primary and Metastatic Melanomas With RAF1 and BRAF Fusions
Cecilia Lezcano, Israel S Kasago, Haiming Tang, et al.
JAMA Oncology
|
January 30, 2025
Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy
Sarah E Lochrin, Hannah L Kalvin, James W Smithy, et al.
Translational Vision Science & Technology
|
April 25, 2015
Confocal Adaptive Optics Imaging of Peripapillary Nerve Fiber Bundles: Implications for Glaucomatous Damage Seen on Circumpapillary OCT Scans
Donald C Hood, Monica F Chen, Dongwon Lee, et al.
JCO Precision Oncology
|
June 1, 2023
Response to Repotrectinib After Development of <i>NTRK</i> Resistance Mutations on First- and Second-Generation TRK Inhibitors
Monica F Chen, Soo-Ryum Yang, Jinru Shia, et al.
JCO Precision Oncology
|
May 15, 2025
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With <i>EGFR</i>-Mutant Lung Cancer Treated With Osimertinib
Monica F Chen, Mark Y Jeng, Jennifer Ma, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 30, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination
James W Smithy, Victoria Ciallella, Claire Thant, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 29, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination
James W Smithy, Victoria Ciallella, Claire Thant, et al.
JTO Clinical and Research Reports
|
August 30, 2023
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced <i>ALK</i>- or <i>ROS1</i>-Rearranged NSCLC: A Brief Report
Rohit Thummalapalli, Noura J Choudhury, Fiona Ehrich, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
August 23, 2023
Superior sulcus non-small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management
Kaitlin McLaughlin, Kay See Tan, Joe Dycoco, et al.
Page
of 3